MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio. The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application.

MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio. The product pipeline includes real-time kidney function monitoring, a huge leap forward in the world of nephrology. The clinical history and road to FDA and European approvals on this component of the MediBeacon pipeline as well as other developments related to the platform of fluorescent agents and their potential clinical application.

GDm-Health is a digital therapeutic for remotely managing pregnant women with diabetes in pregnancy. GDm-Health enables remote monitoring of pregnant women to comply with social distancing guidance during the COVID-19 pandemic. GDm-Health helps this high-risk group monitor their condition and be managed by clinicians, safely at home. Clinicians use the GDm-Health desktop application to review readings - algorithms prioritise patients in greatest need. GDm-Health can be used at pre conception, diagnosed gestational diabetes and suspected gestational diabetes, throughout the pregnancy and post delivery until clinically necessary. GDm-Health is regulated, CE marked, HIPPA compliant and adopted broadly with the UK. GDm-Health comprises a free smartphone application that can connect to a blood glucose monitor via Bluetooth - patients input blood glucose readings, add notes and request callbacks if needed.

Our Discovery Sciences and Software Product divisions work together towards one goal: To connect patients, clinicians and researchers, which collectively help healthcare professionals deliver better patient care while curating vital data to support the next generation of medical research.